Evaluation RuleDecision layer

LegUpRx Rule: Only Resell It to Clients Who Already Own the Patient Relationship

Should our agency resell LegUpRx to a client, and which client type makes that resale defensible? Resell LegUpRx only to consumer wellness clients with an existing patient or member base, and decline any engagement where the buyer is a B2B SaaS company or another agency.

By InnovaAI ResearchPublished

“Should our agency resell LegUpRx to a client, and which client type makes that resale defensible?”

Resell LegUpRx only to consumer wellness clients with an existing patient or member base, and decline any engagement where the buyer is a B2B SaaS company or another agency.

Common Mistake

Agencies treat LegUpRx like the other white-label builders in this category and pitch it to B2B SaaS or agency clients as a rebrandable product, then discover there is no consumer audience to convert and the $730/mo retainer has no renewal base behind it.

Why This Works

LegUpRx handles clinical licensing, compliance, and pharmacy fulfillment, so the partner's only real asset is distribution to end consumers. The verdict is explicit that the model suits agencies with direct end-customer relationships and fails for agencies selling to other agencies. The $730/mo Starter Telehealth Launch fee only clears against a client base that can be marketed to immediately, since margin comes from renewals on medication programs priced above LegUpRx wholesale cost.

Apply When
  • •The client already sells to consumers in a wellness vertical (gym, chiropractic clinic, spa, wellness coaching) and holds a customer list it can market to directly
  • •The client has no medical license and no clinical staff, so LegUpRx's licensed clinician network and HIPAA infrastructure carry the entire compliance load
  • •The agency can absorb roughly 16 hours of setup plus 3 hours per month per client, matching the Starter Telehealth Launch effort profile
  • •The client accepts a $730/mo agency fee on top of LegUpRx wholesale cost and prices its own medication programs above that floor
  • •The client's state footprint avoids the 46-state restriction on the Anti-Aging Skin DNA Test offer (excluded: NY, PA, RI, MD)
Open the LegUpRx courseLegUpRx decision recordBrowse the Academy

More on LegUpRx